Summit Therapeutics (Summit Therapeutics) ROCE % : -93.76% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Summit Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Summit Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -93.76%.

Summit Therapeutics ROCE % Historical Data

The historical data trend for Summit Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Summit Therapeutics ROCE % Chart

Summit Therapeutics Annual Data

Trend

Jan14

Jan15

Jan16

Jan17

Jan18

Jan19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

17.98

-72.65

-103.73

-20.86

-148.15

Summit Therapeutics Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-17.09	-495.15	-21.09	-44.94	-93.76

Summit Therapeutics ROCE % Calculation

Summit Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-598.467	/	( ( (664.168 - 38.782)	+	(202.949 - 20.405) )	/ 2 )
	=	-598.467	/	( (625.386	+	182.544)	/ 2 )
	=	-598.467	/	403.965
	=	-148.15 %

Summit Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-134.68	/	( ( (218.476 - 113.742)	+	(202.949 - 20.405) )	/ 2 )
	=	-134.68	/	( ( 104.734	+	182.544 )	/ 2 )
	=	-134.68	/	143.639
	=	-93.76 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Summit Therapeutics (NAS:SMMT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Summit Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Summit Therapeutics (Summit Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics Inc (NAS:SMMT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025

Website

https://www.smmttx.com

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Executives

Ankur Dhingra	officer: Chief Financial Officer	C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Maky Zanganeh	director	51 ADAM WAY, ATHERTON CA 94027
Manmeet Singh Soni	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Robert W Duggan	director, 10 percent owner, officer: See Remarks	611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Yu Xia	director	6 SHENNONG ROAD, TORCH DEVELOPMENT ZONE, ZHONGSHAN, GUANGDONG F4 528437
Robert F. Booth	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Alessandra Cesano	director	700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Urte Gayko	director	C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Kenneth A Clark	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Jeffrey R Maranian	officer: VP, Corporate Controller	C/O SUMMIT THERAPEUTICS INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Luhua Wang	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
David Jonathan Powell	officer: Chief Scientific Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Camilla Graham	officer: Chief Clinical Affairs Officer	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ventzislav Stefanov	director, officer: See Remarks	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ujwala Mahatme	director	ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142